ArticleHuman molecular genetics2015
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
Open access · hybridAbstract read
In one paragraph
Article in Human molecular genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
9.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Genome-wide association identifies seven loci for pelvic organ prolapse in Iceland and the UK Biobank.Communications biology · 2020Pooled it
- Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.Nature communications · 2018Pooled it
- Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution.Human molecular genetics · 2017Pooled it
- Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers.Scientific reports · 2016Pooled it
- Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health technology assessment (Winchester, England) · 2020Trial
- Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Trial
- The role of apoptotic genetic polymorphisms in prostate cancer susceptibility in a North West Spain population.Molecular genetics and genomics : MGG · 2026Article
- Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study.Cancers · 2025Article
- Circulating chromatin reveals the effects of disease-associated variants on gene regulation.bioRxiv : the preprint server for biology · 2025Article
- Family History of Early Onset or Lethal Prostate Cancer and the Risk of Prostate Cancer Death in Sweden.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Emerging tools for the early detection of prostate cancer.BJUI compass · 2025Review
- Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort.PLoS computational biology · 2024Article
- Cistrome Data Browser: integrated search, analysis and visualization of chromatin data.Nucleic acids research · 2024Article
- Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nature genetics · 2023Article
- A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nature communications · 2023Article
- Association between obesity and frequency of high-grade prostate cancer on biopsy in men: A single-center retrospective study.Molecular and clinical oncology · 2022Article
- Novel role of prostate cancer risk variant rs7247241 on PPP1R14A isoform transition through allelic TF binding and CpG methylation.Human molecular genetics · 2022Article
- A microRNA Transcriptome-wide Association Study of Prostate Cancer Risk.Frontiers in genetics · 2022Article
- H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility.American journal of human genetics · 2021Article
- Parallel Reporter Assays Identify Altered Regulatory Role of rs684232 in Leading to Prostate Cancer Predisposition.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
79 authors at 20 institutions in 14 countries.
Ali Amin Al OlamaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory.
Tokhir DadaevDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Dennis J HazelettDepartment of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA, Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA.
Qiuyan LiMedical College, Xiamen University, Xiamen, China.
Daniel LeongamornlertDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Edward J SaundersDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Sarah StephensDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Clara Cieza-BorrellaDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Ian WhitmoreDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Sara Benlloch GarciaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory.
Graham G GilesCancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, VIC, Australia, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health.
Melissa C SoutheyGenetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia.
Liesel FitzgeraldTissupath Pty Ltd., Melbourne, VIC, Australia.
Henrik GronbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Markus AlyDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden, Department of Clinical Sciences, Danderyds Hospital, Stockholm, Sweden.
Brian E HendersonDepartment of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA.
Fredrick SchumacherDepartment of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA.
Christopher A HaimanDepartment of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA.
Johanna SchleutkerDepartment of Medical Biochemistry and Genetics Institute of Biomedicine, University of Turku, Turku, Finland, BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland.
Tiina WahlforsBioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland.
Teuvo L TammelaDepartment of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland.
Børge G NordestgaardDepartment of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Tim J KeyCancer Epidemiology, Nuffield Department of Population Health.
Ruth C TravisCancer Epidemiology, Nuffield Department of Population Health.
David E NealDepartment of Oncology, Addenbrooke's Hospital, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK.
Jenny L DonovanSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK, Faculty of Medical Science, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Paul PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, Strangeways Laboratory.
Nora PashayanCentre for Cancer Genetic Epidemiology, Department of Oncology, Strangeways Laboratory, Department of Applied Health Research, University College London, London, UK.
Kay-Tee KhawClinical Gerontology Unit, University of Cambridge, Cambridge, UK.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.
Stephen N ThibodeauMayo Clinic, Rochester, MN, USA.
Shannon K McdonnellMayo Clinic, Rochester, MN, USA.
Daniel J SchaidMayo Clinic, Rochester, MN, USA.
Christiane MaierDepartment of Urology, University Hospital Ulm, Ulm, Germany.
Walther VogelInstitute of Human Genetics, University of Ulm, Ulm, Germany.
Manuel LuedekeDepartment of Urology, University Hospital Ulm, Ulm, Germany.
Kathleen HerkommerDepartment of Urology, Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munich, Germany.
Adam S KibelDivision of Urologic Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, USA.
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Dominika WokołorczykInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Wojciech KluzniakInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Lisa Cannon-AlbrightDivision of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA, George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), Heidelberg, Germany.
Katja ButterbachDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), Heidelberg, Germany.
Volker ArndtDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jong Y ParkDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Thomas SellersDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Hui-Yi LinBiostatistics Program, Moffitt Cancer Center, Tampa, FL, USA.
Chavdar SlavovDepartment of Urology and Alexandrovska University Hospital, Medical University, Sofia, Bulgaria.
Radka KanevaDepartment of Medical Chemistry and Biochemistry, Molecular Medicine Center, Medical University, Sofia, Bulgaria.
Vanio MitevDepartment of Medical Chemistry and Biochemistry, Molecular Medicine Center, Medical University, Sofia, Bulgaria.
Jyotsna BatraAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, Australia.
Judith A ClementsAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, Australia.
Amanda SpurdleMolecular Cancer Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal, Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
Paula PauloDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Sofia MaiaDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Hardev PandhaThe University of Surrey, Guildford, Surrey, UK.
Agnieszka MichaelThe University of Surrey, Guildford, Surrey, UK.
Andrzej KierzekThe University of Surrey, Guildford, Surrey, UK.
Koveela GovindasamiDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Michelle GuyDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Artitaya LophatonanonInstitute of Population Health, University of Manchester, Manchester, UK, Warwick Medical School, University of Warwick, Coventry, UK.
Kenneth MuirInstitute of Population Health, University of Manchester, Manchester, UK, Warwick Medical School, University of Warwick, Coventry, UK.
Ana ViñuelaDepartment of Twin Research & Genetic Epidemiology, King's College London, London, UK.
Andrew A BrownNORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Department of Genetic Medicine and Development, University of Geneva, Switzerland and.
PRACTICAL Consortium
COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative
Australian Prostate Cancer BioResource
UK Genetic Prostate Cancer Study Collaborators
UK ProtecT Study Collaborators
Mathew FreedmanDana Farber Cancer Institute, Boston, MA, USA.
David V ContiDepartment of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA, Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA.
Douglas EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory.
Gerhard A CoetzeeDepartment of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA, Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, USC, Los Angeles, CA, USA.
Rosalind A EelesDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Zsofia Kote-JaraiDivision of Genetics and Epidemiology, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK, zsofia.kote-jarai@icr.ac.uk.
Royal Marsden NHS Foundation Trust · GBUSC Norris Comprehensive Cancer Center · USGerman Cancer Research Center · DEInternational Hereditary Cancer Center · PLMayo Clinic in Arizona · USMoffitt Cancer Center · USPrimary Health Care · QAUniversity of Surrey · GBCancer Research UK · GBInstituto Português de Oncologia Francisco Gentil · PTKarolinska Institutet · SEMedical University of Sofia · BGNuffield Health · GBQueensland University of Technology · AUUniversity Hospital Ulm · DEUniversity of Manchester · GBAlexandrovska Hospital · BGBrigham and Women's Hospital · USCancer Council Victoria · AUDana-Farber Cancer Institute · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MEpidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4MCancer Research UK 10119Cancer Research UK 10124Cancer Research UK 10588Cancer Research UK 12518Cancer Research UK 13065Cancer Research UK 14136Cancer Research UK 15007Cancer Research UK 16491Cancer Research UK 16561Cancer Research UK 16563Cancer Research UK 17528Cancer Research UK 19170Cancer Research UK 19727Cancer Research UK C1287/A10118Cancer Research UK C16913/A6135Cancer Research UK C5047/A10692Cancer Research UK C5047/A3354Cancer Research UK C5047/A7357Medical Research Council G0401527Medical Research Council G1000143NCI NIH HHS 1 U19 CA 148537-01NCI NIH HHS P30 CA015704NCI NIH HHS U19 CA148537
Abstract
Genome-wide association studies (GWAS) have identified numerous common prostate cancer (PrCa) susceptibility loci. We have fine-mapped 64 GWAS regions known at the conclusion of the iCOGS study using large-scale genotyping and imputation in 25 723 PrCa cases and 26 274 controls of European ancestry. We detected evidence for multiple independent signals at 16 regions, 12 of which contained additional newly identified significant associations. A single signal comprising a spectrum of correlated variation was observed at 39 regions; 35 of which are now described by a novel more significantly associated lead SNP, while the originally reported variant remained as the lead SNP only in 4 regions. We also confirmed two association signals in Europeans that had been previously reported only in East-Asian GWAS. Based on statistical evidence and linkage disequilibrium (LD) structure, we have curated and narrowed down the list of the most likely candidate causal variants for each region. Functional annotation using data from ENCODE filtered for PrCa cell lines and eQTL analysis demonstrated significant enrichment for overlap with bio-features within this set. By incorporating the novel risk variants identified here alongside the refined data for existing association signals, we estimate that these loci now explain ∼38.9% of the familial relative risk of PrCa, an 8.9% improvement over the previously reported GWAS tag SNPs. This suggests that a significant fraction of the heritability of PrCa may have been hidden during the discovery phase of GWAS, in particular due to the presence of multiple independent signals within the same region.
Indexed as
Polymorphism, Single NucleotideChromosome MappingGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansLinkage DisequilibriumMaleProstatic NeoplasmsWhite People
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.